Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 4/20 | 0.55 |
| ▸ | EDNRB | P24530 | 4/20 | 0.54 |
| ▸ | EDNRA | P25101 | 4/20 | 0.54 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.40 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.37 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.35 |
| ▸ | GAPDH | P04406 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | HSPA1A | P0DMV8 | 1/20 | 0.35 |
| ▸ | MIF | P14174 | 1/20 | 0.35 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1477851 | 1.00 | KDM1A (0.55) | KDM1AEDNRBEDNRACAMK2ASRD5A1 | |
| SCHEMBL12749435 | 1.00 | KDM1A (0.55) | KDM1AEDNRBEDNRACAMK2ASRD5A1 | |
| SCHEMBL1477468 | 1.00 | KDM1A (0.55) | KDM1AEDNRBEDNRACAMK2ASRD5A1 | |
| SCHEMBL29134899 | 0.87 | EDNRB (0.50) | KDM1AEDNRBEDNRACAMK2ASRD5A1 | |
| SCHEMBL3073942 | 0.82 | EDNRB (0.41) | KDM1AEDNRBEDNRAKDM1BFFAR1 | |
| SCHEMBL17276195 | 0.82 | EDNRB (0.41) | KDM1AEDNRBEDNRAKDM1BFFAR1 | |
| SCHEMBL1478108 | 0.79 | KDM1A (0.47) | KDM1AEDNRBEDNRAMEN1POLB | |
| SCHEMBL12749434 | 0.79 | KDM1A (0.47) | KDM1AEDNRBEDNRAMEN1POLB | |
| SCHEMBL1478110 | 0.79 | KDM1A (0.47) | KDM1AEDNRBEDNRAMEN1POLB | |
| SCHEMBL18940272 | 0.78 | FFAR1 (0.46) | KDM1AEDNRBEDNRAFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7915295-B2 | Viricides; HIV antivirals effective against problematic drug escape mutants; N-[(1S,1aR,7bR)-4,7-difluoro-1,1a,2,7b-tetrahydrocyclopropa[c]chromen-1-yl]-N'-[5-(4-(sulfonamido)phenoxy)-2-pyridinyl]urea | MEDIVIR AB (SE) | 2011-03-29 | — | — | US | disclosed |
| EP-1701942-B1 | NON-NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITORS | MEDIVIR AB (SE) | 2009-12-09 | — | — | EP | disclosed |
| US-7517992-B2 | Non-nucleoside reverse transcriptase inhibitors | MEDIVIR AB (SE) | 2009-04-14 | — | — | US | disclosed |
| US-20080070951-A1 | Non-Nucleotide Reverse Transcriptase Inhibitors | MEDIVIR AB (SE) | 2008-03-20 | — | — | US | disclosed |
| EP-1701942-A1 | NON-NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITORS | MEDIVIR AB (SE) | 2006-09-20 | — | — | EP | disclosed |
| US-20060167055-A1 | Non-nucleoside reverse transcriptase inhibitors | MEDIVIR AB (SE) | 2006-07-27 | — | — | US | disclosed |
| WO-2005066131-A1 | NON-NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITORS | MEDIVIR AB (SE) | 2005-07-21 | — | — | WO | disclosed |
| EP-1423368-A1 | UREA AND THIOUREA DERIVATIVES AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MEDIVIR AB (SE) | 2004-06-02 | — | — | EP | disclosed |
| US-6610714-B2 | HIV viricides | MEDIVIR AB (SE) | 2003-08-26 | — | — | US | disclosed |
| US-20030092743-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MEDIVIR AB (SE) | 2003-05-15 | — | — | US | disclosed |
| WO-2003020705-A1 | UREA AND THIOUREA DERIVATIVES AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MEDIVIR AB (SE) | 2003-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092743-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | SUB1, HCFC1, CCR1 | KDM1A 268/4885EDNRB 3392/4885EDNRA 3246/4885 |
| US-20060167055-A1 | Non-nucleoside reverse transcriptase inhibitors | POLR2H, POLR2E, POLR1E | KDM1A 2082/4885EDNRB 2287/4885EDNRA 2441/4885 |
| US-20080070951-A1 | Non-Nucleotide Reverse Transcriptase Inhibitors | RCOR1, RRM2, POLR1A | KDM1A 1736/4885EDNRB 1557/4885EDNRA 1128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.